Myeloma Crowd Radio

Upcoming Shows

MCRI High-Risk Myeloma Series: Dr. Craig Hofmeister, MD, using CAR T cells to target high-risk myeloma – Monday, March 30, 11 am CST

0

Monday, March 30, 9 am PST, 10 am MST, 11 am CST, Noon EST

Call In by Phone to Listen Live: (347) 637-2631 or Listen Live Via Computer

Join us for this first interview on Myeloma Crowd Radio highlighting the new Myeloma Crowd Research Initiative on high-risk myeloma. For the first time, patients and doctors are joining together to find and fund research for a patient group that is desperate for new options. The MCRI initiative reached out the the worldwide community and asked them to submit their research proposals for high-risk patients. We received 36 high quality proposals from all over the world. The MCRI Scientific Advisory Board then scored the proposals, selecting 10 for further review. These ten will be included in the Myeloma Crowd Radio/MCRI series on high-risk.  

As part of this series, Dr. Craig Hofmeister, MD from Ohio State University will share his work to use engineered CAR T cells to specifically target high-risk multiple myeloma. He will describe how CAR T cells are engineered, how they work, and what types of high-risk myeloma will be affected by this approach. CAR T cell therapies have received significant attention lately in myeloma and we look forward to learning more about the work being done on this important and relevant topic.

Dr. Craig Hofmeister, MD is Associate Professor of Medicine at Ohio State University and is Lead of the Section of Plasma Cell Dyscrasias. In addition to his myeloma research interests, he is an attending physician in the Lymphoma, Myeloma and Bone Marrow Transplant Service. He is an ad-hoc reviewer of publications including Blood, Journal of Clinical Oncology, Clinical Cancer Research, and British Journal of Haematology. He is the recipient of the Imagine MMORE Award, MMORE (Multiple Myeloma Opportunities for Research & Education), Business First’s Forty Under 40 Award (Columbus Dispatch, Columbus, Ohio) and Early Career Achievement Award, The Ohio State University College of Medicine.

Special thanks to our Myeloma Crowd Radio Episode sponsor, Takeda Oncology.

Myeloma Crowd Radio Episodes